Recent developments in anticancer nitric oxide donors

Bibliography

• Nitric oxide: biology and pathobiology. Ignarro LJ (Ed.) Academic Press, San Diego (2000).
   Google Scholar
• ••Comprehensive book on NO.
   Google Scholar
• FRIEBE A, KOESLING D: Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res. (2003) 93(2):96–105.
   PubMed Web of Science ®Google Scholar
• PILZ RB, CASTEEL DE: Regulation of gene expression by cyclic GM. Circ. Res. (2003) 93(11):1034–1046.
   PubMed Web of Science ®Google Scholar
• BINDER C, SCHULZ M, HIDDEMANN W, OELLERICH M: Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-a-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab. Invest. (1999) 79(12):1703–1712.
   PubMed Web of Science ®Google Scholar
• FARIAS-EISNER R, SHERMAN MP, AEBERHARD E, CHAUDHURI G: Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc. Nat] Acad. Sci. USA (1994) 91(20):9407–9411.
   PubMed Web of Science ®Google Scholar
• BOYD CS, CADENAS E: Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol. Chem. (2002) 383(3/4):411–423.
   Google Scholar
• XIE K, HUANG S: Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Rad. Biol. Med. (2003) 34(8):969–986.
   PubMed Web of Science ®Google Scholar
• FELLEY-BOSCO E, MIRKOVITCH J, AMBS S et at Nitric oxide and ethylnitrosourea: relative mutagenicity in the p53 tumor supressor and hypoxanthine-phosphoribosyltransferase genes. Carcinogenesis (1995) 16(9):2069–2074.
   PubMed Web of Science ®Google Scholar
• WINK DA, MITCHELL JB: Nitric oxide and cancer: an introduction. Free Rad. Biol. Med. (2003) 34(8):951–954.
   PubMed Web of Science ®Google Scholar
• ••Recent review of NO and cancer.
   Google Scholar
• HOFSETH LJ, HUSSAIN SP, WOGAN GN, HARRIS CC: Nitric oxide in cancer and chemoprevention. Free Rad. Biol. Med. (2003) 34(8):955–968.
   PubMed Web of Science ®Google Scholar
• •Review of NO and carcinogenesis.
   Google Scholar
• JIA Q, JANCZUK AJ, CAI T et al: NO donors with anticancer activity. Expert Opin. Ther. Patents(2002) 12(6):819–826.
   Web of Science ®Google Scholar
• •Review of anticancer NO donors.
   Google Scholar
• SAAVEDRA JE, SHAMI PJ, WANG LY et al.: Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: M vitro antileukemic activity. .1 Med. Chem. (2000) 43(2):261–269.
   Google Scholar
• SAAVEDRA JE, SRINIVASAN A, BONIFANT CL et al: The secondary amine/nitric oxide complex ion R2N[I\1(0)N0]- as nucleophile and leaving group in SNAr reactions. I. Org. Chem. (2001) 66(9):3090–3098.
   PubMed Web of Science ®Google Scholar
• SHAMI PJ, SAAVEDRA JE, WANG LY et al.: JS-K, a glutathione/glutathione Stransferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Titer. (2003) 2(4):409–417.
   PubMed Web of Science ®Google Scholar
• ••Mechanism studies of JS-K.
   Google Scholar
• REN Z, KAR S, WANG Z et al: JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. I Cell. Physiol (2003) 197(3):426–434.
   PubMed Web of Science ®Google Scholar
• •Mechanism of inhibition of cell growth by JS-K.
   Google Scholar
• CAI TB, TANG X, NAGORSKI J, BRAUSCHWEIGER PG, WANG PG: Synthesis and cytotoxicity of 5-fluorouracil/ diazeniumdiolate conjugates. Bioorg. Med. Chem. (2003) 11(23):4971–4975.
   PubMed Web of Science ®Google Scholar
• WINK DA, COOK JA, CHRISTODOULOU D et al.: Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide (1997) 1(1):88–94.
   PubMed Web of Science ®Google Scholar
• JIA L, SCHWEIZER J, WANG Y et al: Effect of nitric oxide on cytotoxicity of Taxol: enhanced Taxol transcellular permeability. Biochem. Pharmacol (2003) 66(11):2193–2199.
   PubMed Web of Science ®Google Scholar
• KONOVALOVA NE GONCHAROVA SA, VOLKOVA LM et al: Nitric oxide donor increases the efficiency of cytostatic therapy and retards the development of drug resistance. Nitric Oxide (2003) 8(1):59–64.
   PubMed Web of Science ®Google Scholar
• TAKETO MM: Cyclooxygenase-2 inhibitors in tumorigenesis (partNatl. Cancer Inst. (1998) 90(21):1609–1620.
   Google Scholar
• TAKETO MM: Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). Natl. Cancer Inst. (1998) 90(20):1529–1536.
   Google Scholar
• JANNE PA, MAYER RJ: Chemoprevention of colorectal cancer. N Engl. J. Med. (2000) 342(26):1960–1968.
   PubMed Web of Science ®Google Scholar
• JONES MK, WANG H, PESKAR BM et al.: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5(12):1418–1423.
   PubMed Web of Science ®Google Scholar
• DUBOIS RN, GIARDIELLO FM, SMALLEY WE: Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Castroenterol. Clin. North Am. (1996) 25(4):773–791.
   PubMed Web of Science ®Google Scholar
• LAVAGNA C, DEL SOLDATO P, BURGAUD J-L, RAMPAL P: Nitric oxide-releasing non steroidal anti-inflammatory drugs: A new generation of anti-tumoral molecules. Carr: Cancer Drug Targets (2003) 3(6):407–426.
   PubMed Web of Science ®Google Scholar
• •Review on NSAIDs as anticancer drugs.
   Google Scholar
• HERENDEEN JM, LINDLEY C: Use of NSAIDs for the chemoprevention of colorectal cancer. Ann. Pharmacother. (2003) 37(11):1664–1674.
   PubMed Web of Science ®Google Scholar
• SKELLY MM, HAWKEY CJ: Dual COX inhibition and upper gastrointestinal damage. Curr. Pharm. Design (2003) 9(27):2191–2195.
   PubMed Web of Science ®Google Scholar
• WALLACE JL, DEL SOLDATO P: The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. (2003) 17(1):11–20.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JL, BORGO S, HASAN I eta].: Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer chemoprevention. Cancer Res. (2001) 61(8):3285–3289.
   Google Scholar
• WILLIAMS JL, KASHFI K, OUYANG N et al.: NO-donating aspirin inhibits intestinal carcinogenesis in fl/fin (APC4'1) mice. Biochem. Biophys. Res. Comm. (2004) 313(3):784–788.
   PubMed Web of Science ®Google Scholar
• NATH N, KASHFI K, CHEN J, RIGAS B: Nitric oxide-donating aspirin inhibits I3-catenin/T cell factor (TCF) signaling in 5W480 colon cancer cells by disrupting the nuclear P-catenin/TCF association. Proc. Natl. Acad. Sci. USA (2003) 100(22):12584–12589.
   PubMed Web of Science ®Google Scholar
• •Recent mechanism study of NO-aspirin.
   Google Scholar
• BARON JA, COLE BF, SANDLER RS et al.: A randomized trial of aspirin to prevent colorectal adenomas. N Engl. J. Med. (2003) 348(10):891–899.
   PubMed Web of Science ®Google Scholar
• SANDLER RS, HALABI S, BARON JA et al.: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl. J. Med. (2003) 348(10):883–890.
   PubMed Web of Science ®Google Scholar
• SHIFF SJ, SHIVAPRASAD P, SANTINI DL: Cyclooxygenase inhibitors: drugs for cancer prevention. Curr: Opin. Pharmacol. (2003) 3(4):352–361.
   PubMed Web of Science ®Google Scholar
• TSUMORI M, TANAKA J, KOSHIMURA K et al.: Cytotoxic effect of nitric oxide on humna hematological malignant cells. Acta. Biochim. Polon. (2002) 49(4139–144.
   Web of Science ®Google Scholar
• BABICH H, ZUCKERBRAUN HL: In vitro cytotoxicity of glyco-..Cnitrosothiols a novel class of nitric oxide donors. Toxicol. Vitro (2001) 15(3):181–190.
   Google Scholar
• WU X, TANG X, XIAN M, BRAUSCHWEIGER PG, WANG PG: Synthesis and cytotoxicities of mannose conjugated ..Cnitroso-N-acetylpenicillamine (SNAP). Bioorg. Med. Chem. (2002) 10(7):2303–2307.
   Google Scholar
• YIP D, AHMAD A, KARAPETIS CS, HAWKINS CA, HARPER PG: Matrix metalloproteinase inhibitors: applications in oncology. Invest. New Drugs (1999) 17(4):387–399.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, GRAY R, GIANTONIO B, O'DWYER P, COMIS RL: Evaluation antiangiogenesis agents in the clinic: the eastern cooperative oncology group portfolio of clinical trials. Clin. Cancer Res. (2004) 10(4):1206–1211.
   PubMed Web of Science ®Google Scholar
• GRAHAM CH, FORSDIKE J, FITZGERALD CJ, MACDONALD GS: Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int. J. Cancer (1999) 80(4):617–623.
   PubMed Web of Science ®Google Scholar
• BROWN JM: The hypoxic cell: a target for selective cancer therapy-eighteenth. Cancer Res. (1999) 59(23):5863–5870.
   PubMed Web of Science ®Google Scholar
• FREDERIKSEN LJ, SIEMENS DR, HEATON JP et al.: Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate. Urol. (2003) 170(3):1003–1007.
   Web of Science ®Google Scholar
• HO Y-P, AU-YEUNG SCF, TO KKW: Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med. Res. Rev (2003) 23(5):633–655.
   PubMed Web of Science ®Google Scholar
• GALANSKI M, ARION VB, JAKUPEC MA, KEPPLER BK: Recent developments in the field of tumor-inhibiting metal complexes. Curl: Pharm. Des. (2003) 9(25):2078–2089.
   PubMed Web of Science ®Google Scholar
• ZHANG XK: Vitamin A and apoptosis in prostate cancer. Endocr. Relat. Cancer (2002) 9(2):87–102.
   PubMed Web of Science ®Google Scholar
• FREEMANTLE SJ, SPINELLA MJ, DMITROVSKY E: Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene (2003) 22(447305–7315.
   Web of Science ®Google Scholar
• •Review of retinoids in cancer therapy.
   Google Scholar
• SIMEONE A-M, EKMEKCIOGLU S, BROEMELING LD, GRIMM EA, TARI AM: A novel mechanism by which N-(4-hydroxyphenyflretinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol. Cancer Ther. (2002) 1(12):1009–1017.
   PubMed Web of Science ®Google Scholar
• WONG A, TOTH I: Lipid, sugar and liposaccharide-based delivery systems. Curl: Med. Chem. (2001) 8(9):1123–1136.
   PubMed Web of Science ®Google Scholar
• PAUWELS EKJ: 18F-labeled fluorodeoxyglucose for PET imaging: the working mechanism and its clinical implication. Drugs Fut. (2001) 26(7):659–668.
   Web of Science ®Google Scholar
• RAMASAMY R: Aldose reductase: a novel target for cardioprotective interventions. Curr: Drug Targets (2003) 4(8):625–632.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA SK, RAMANA KV, CHANDRA D, SRIVASTAVA S, BHATNAGAR A: Regulation of aldose reductase and the polyol pathway activity by nitric oxide. Chem. Biol. Interact. (2003) 143–144:333–340.
   Google Scholar
• SEO HG, NISHINAKA T, YABE -NISHIMURA C: Nitric oxide up-regulates aldose reductase expression in rat vascular smooth muscle cells: a potential role for aldose reductase in vascular remodeling. Mol. Pharmacol. (2000) 57(4):709–717.
   PubMed Web of Science ®Google Scholar
• ALLAKER EP, MENDEZ LSS, HARDIE JM, BENJAMIN N: Antimicrobial effect of acidified nitrite on periodontal bacteria. Oral Microbiol. Immunol. (2001) 16(4):253–256.
   PubMedGoogle Scholar
• PATTERSON LH, MURRAY GI: Tumour cytochrome P450 and drug activation. Curr: Pharm. Des. (2002) 8:1335–1347.
   Google Scholar
• EVERETT SA, NAYLOR MA, STRATFORD MR et al.: Aromatic oxime derivatives are substrates for tumor-associated cytochrome P450s and prodrugs for nitric oxide. Portland Press Proc. (2000) 16(Biology of Nitric Oxide Part 7):140.
   Google Scholar
• WANG PG, XIAN M, TANG X et al.: Nitric oxide donors: chemical activities and biological applications. Chem. Rev (2002) 102(4):1091–1134.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review on NO donors.
   Google Scholar